Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Mattia Galli, Domenico D’Amario, Carmelo Sofia, Marcello Vaccarella, Filippo Crea & Nadia Aspromonte. (2018) Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure. Expert Opinion on Drug Metabolism & Toxicology 14:12, pages 1273-1285.
Read now
Read now
Marco Tuccori, Irma Convertino, Maria Teresa Galiulo, Alessandra Marino, Alice Capogrosso-Sansone & Corrado Blandizzi. (2017) Diabetes drugs and the incidence of solid cancers: a survey of the current evidence. Expert Opinion on Drug Safety 16:10, pages 1133-1148.
Read now
Read now
Matthew R. Weir. (2016) The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors. Postgraduate Medicine 128:3, pages 290-298.
Read now
Read now
Articles from other publishers (9)
Yasuhiro Iijima, Masafumi Nakayama, Takashi Miwa, Fumiyoshi Yakou, Hirofumi Tomiyama, Junpei Shikuma, Rokuro Ito, Akihiko Tanaka, Naoki Manda & Masato Odawara. (2023) Nephroprotective Effects of Dapagliflozin in Patients with Type 2 Diabetes. Internal Medicine 62:5, pages 681-688.
Crossref
Crossref
Krisztina Kupai, Tamás Várkonyi, Szilvia Török, Viktória Gáti, Zsolt Czimmerer, László G. Puskás & Gábor J. Szebeni. (2022) Recent Progress in the Diagnosis and Management of Type 2 Diabetes Mellitus in the Era of COVID-19 and Single Cell Multi-Omics Technologies. Life 12:8, pages 1205.
Crossref
Crossref
Stefan Balkanski. (2021) Dapagliflozin – structure, synthesis, and new indications. Pharmacia 68:3, pages 591-596.
Crossref
Crossref
Johan H Jendle, Francisco J Ampudia-Blasco, Martin Füchtenbusch & Paolo Pozzilli. (2021) Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination. European Endocrinology 1:1, pages 12.
Crossref
Crossref
Dyah Ari Nugrahaningrum, Olivia Marcelina, Caiping Liu, Shourong Wu & Vivi Kasim. (2020) Dapagliflozin Promotes Neovascularization by Improving Paracrine Function of Skeletal Muscle Cells in Diabetic Hindlimb Ischemia Mice Through PHD2/HIF-1α Axis. Frontiers in Pharmacology 11.
Crossref
Crossref
Kenan Çadırcı, Özlem Özdemir Tozlu & Hasan Türkez. (2019) The in vitro cytotoxicity, genotoxicity and oxidative damage potential of dapagliflozin, on cultured human blood cells. Turkish Journal of Biochemistry 44:5, pages 692-698.
Crossref
Crossref
Nataša Vidić & Aleksandar Đenić. (2019) Inhibitor natrijum-glukoznog kotransportera tipa 2 - dapagliflozin u terapiji obolelih od diabetes mellitus tipa 2. Medicinski glasnik Specijalne bolnice za bolesti štitaste žlezde i bolesti metabolizma 24:74, pages 29-39.
Crossref
Crossref
Feng Zhu, Jacob Rodriguez, Tianyi Yang, Ilia Kevlishvili, Eric Miller, Duk Yi, Sloane O’Neill, Michael J. Rourke, Peng Liu & Maciej A. Walczak. (2017)
Glycosyl Cross-Coupling of Anomeric Nucleophiles: Scope, Mechanism, and Applications in the Synthesis of Aryl
C
-Glycosides
. Journal of the American Chemical Society 139:49, pages 17908-17922.
Crossref
Crossref
Éva Bokor, Sándor Kun, David Goyard, Marietta Tóth, Jean-Pierre Praly, Sébastien Vidal & László Somsák. (2017)
C
-Glycopyranosyl Arenes and Hetarenes: Synthetic Methods and Bioactivity Focused on Antidiabetic Potential
. Chemical Reviews 117:3, pages 1687-1764.
Crossref
Crossref